Navigation Links
Encouraging HIV/AIDS Vaccine Trial Results Support GeoVax Labs, Inc. Strategy

ATLANTA, Sept. 24 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), was pleased to hear the announcement today of partial success in the recently completed Phase 3 trial in Thailand of a candidate HIV/AIDS vaccine owned by Sanofi-Aventis and Global Solutions for Infectious Diseases. The completed study represents the first HIV/AIDS vaccine trial to show prevention of infection.

Robert McNally, Ph.D., Chief Executive Officer and President stated, "The results are highly encouraging for the clinical studies of our HIV/AIDS vaccine and we congratulate the Thai ministry of Public Health for successful conduct of a groundbreaking trial that included 16,000 volunteers and was supported by multiple agencies including the U.S. Army and the U.S. National Institutes of Health (NIH)."

"The partial success of this trial is very important to the GeoVax vaccine, because the vaccine tested in Thailand, like the GeoVax vaccine, was designed to elicit both T cells and antibody," said Dr. Harriet Robinson, Senior Vice President of Research & Development. "The two vaccines that have failed in previous efficacy trials elicited only antibody or only T cells. This was the first efficacy test of a vaccine that elicited both antibody and T cells and is very encouraging for the GeoVax vaccine, because our vaccine generates higher frequencies of T cells and better quality antibody. Given what we know about the elicited responses observed in this study, and the similarities and differences between our vaccine and the Sanofi-Aventis vaccine, the GeoVax vaccine should be poised for a higher level of protective success than the 30% success rate achieved in Thailand," noted Dr. Robinson.

"Within the two main areas of focus for our HIV/AIDS vaccine - preventative and therapeutic - we continue to make progress," stated Dr. McNally. "The preventative version of the vaccine has advanced to a Phase 2a human clinical trial, which was initiated in February 2009 by the HIV Vaccine Trials Network (HVTN) and continues to have steadily increasing enrollment. On the therapeutic vaccine, we continue to plan out the details of a Phase 1 human clinical trial and expect to begin this trial, assuming U.S. Food and Drug Administration (FDA) concurrence, in the first quarter of 2010."

The Technology

GeoVax's unique two component vaccine, a recombinant DNA and a recombinant modified vaccinia Ankara (MVA), is designed to stimulate both anti-HIV T cell and anti-HIV antibody immune responses. GeoVax's DNA and MVA vaccines are used in a prime-boost protocol in which priming is done with the DNA and boosting with the MVA. GeoVax is also investigating a potentially simpler regimen in which MVA is used for both priming and boosting. Both the DNA and MVA express the three major proteins of the AIDS virus: Gag, Pol, and Env, and produce non-infectious virus-like-particles. These particles contain proteins that mimic more than half of the components of the AIDS virus, but cannot cause AIDS. This multi-protein approach is designed to elicit a broad multi-target protective T cell response. The Env protein is designed to elicit a protective antibody response against the natural form of the virus envelope glycoprotein as well as protective T cells.

"One of the strong features of our vaccines is their stability during manufacture," said Dr. Robinson. "During development, we and our collaborators at the National Institutes of Health persevered to construct vaccines that showed solid stability under commercial manufacturing conditions. We did not advance a vaccine until we had demonstrated stability. We have available inventory and can readily contract manufacture additional product," added Dr. Robinson.

HIV affects the entire globe and comes in a variety of subtypes. Clade B is the predominant subtype in North America, where there are roughly 60,000 new infections each year. Globally, there are about 2.5 million AIDS infections per year, most primarily involving subtypes AG, B, and C. In 2007, UNAIDS reported 1.3 million people living with AIDS in North America and 33.2 million people living with AIDS worldwide. Whereas the Thai trial was conducted with a vaccine targeted for infections endemic to Thailand; the GeoVax vaccine is targeted for the "clade B" type of HIV-1 prevalent in the Americas, Europe and Australia.

About GeoVax Labs, Inc.

GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's AIDS vaccine technology is the subject of 20 issued or filed patent applications. GeoVax AIDS vaccines are designed for use in uninfected people to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person become infected. GeoVax AIDS vaccines also may be effective as a therapeutic treatment (for people already infected with the HIV-1 virus).

GeoVax's core AIDS vaccine technologies were developed by Dr. Harriet Robinson, Senior V.P. of Research and Development, through a collaboration of colleagues at Emory University's Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention (CDC) and GeoVax.

GeoVax's AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded through a cooperative agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided additional support to GeoVax AIDS vaccine development program with a $17 million IPCAVD grant awarded in late 2007.

Safe Harbor Statement

All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions on the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. Certain matters discussed in this news release are forward-looking statements involving certain risks and uncertainties including, without limitation, risks detailed in the Company's Securities and Exchange Commission filings and reports.

SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
2. SemBioSys plant-derived Apo AI(Milano) demonstrates encouraging biologic activity in seven preclinical models
3. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
4. Encouraging high-risk research: DFG approves funding for 2 new Reinhart Koselleck projects
5. Medgenics Announces Encouraging Preliminary Data For Phase I/II Clinical Trial of EPODURE In Renal Anemia
6. Nycomeds Daxas(R) Shows Encouraging Preliminary Results in Phase III COPD Studies
7. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
8. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
9. Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders
10. Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
11. PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis
Post Your Comments:
(Date:12/1/2015)... ... 01, 2015 , ... Park Systems , world leader ... ion conductance microscopy module to Park NX10 that is the only product available ... benefits virtually all materials characterization that require measurements in liquid such as hydrogel, ...
(Date:12/1/2015)... December 1, 2015 Dr. Harry Lander , President of ... as Chief Science Officer and recruits five distinguished ... Lander , President of Regen, expands his role to include ... recruits five distinguished scientists to join advisory team ... expands his role to include serving as ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... Global ... and development stages of a new closed system for isolating adipose-derived stem cells. The ... vascular fraction (SVF) of adipose tissue. SVF is a component of the lipoaspirate obtained ...
(Date:11/30/2015)... Partnership includes an MPP ... the u niversity , s Solid Drug Nanoparticle (SDN) ... - up through cost cuts ... , where licensees based anywhere in the world will have the right to make, ... Africa , where licensees based anywhere in the world will have the right ...
Breaking Biology Technology:
(Date:11/26/2015)... 2015 Research and Markets ( ) ... Sensors - Technology and Patent Infringement Risk Analysis" ... --> Fingerprint sensors using capacitive technology ... fingerprint sensor vendor Idex forecasts an increase of 360% ... devices and of the fingerprint sensor market between 2014 ...
(Date:11/19/2015)... 19, 2015  Although some 350 companies are actively ... a few companies, according to Kalorama Information. These include Roche ... the market share of the 6.1 billion-dollar molecular testing ... Market for Molecular Diagnostic s .    ... still controlled by one company and only a handful ...
(Date:11/17/2015)... -- Paris from 17 th ... Paris from 17 th until 19 th ... has invented the first combined scanner in the world which ... surface. Until now two different scanners were required: one for ... on the same surface. This innovation is an ideal ...
Breaking Biology News(10 mins):